EGFR-Mutated Lung Cancer With T790M-Acquired Resistance in the Brain and Histologic Transformation in the Lung

被引：31

作者：

Scher, Kevin S. ^{[1
]}

Saldivar, Juan-Sebastian ^{[1
]}

Fishbein, Michael ^{[2
]}

Marchevsky, Alberto ^{[3
]}

Reckamp, Karen L. ^{[1
]}

机构：

[1] City Hope Comprehens Canc Ctr, Duarte, CA USA

[2] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[3] Cedars Sinai Med Ctr, Hollywood, CA USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2013年 / 11卷 / 09期

关键词：

ERLOTINIB; GEFITINIB;

D O I：

10.6004/jnccn.2013.0126

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This case report describes the rare occurrence of a T790M resistance mutation found in a central nervous system (CNS) parenchymal metastasis. A concomitant squamous histology transformation in a lung non-T790M-resistant metastasis is also described. The authors hypothesize that this CNS resistance and histology transformation may have resulted from intermittent use of erlotinib treatment. This case report emphasizes the complexities of using erlotinib in the induction setting.

引用

页码：1040 / 1044

页数：5

共 50 条

[21] Risk Factors for Developing T790M Mutation in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer
Ouyang, W.
Xie, C.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E526 - E526
[22] Combined Small and Squamous Transformation in EGFR-mutated Lung Adenocarcinoma
Hakozaki, Taiki
Kitazono, Miyako
Takamori, Mikio
Kiriu, Takahiro
INTERNAL MEDICINE, 2020, 59 (10) : 1291 - 1294
[23] Mechanisms of Acquired Resistance to AZD9291 in EGFR T790M Positive Lung
Oxnard, Geoffrey R.
Thress, Kenneth
Paweletz, Cloud
Stetson, Daniel
Dougherty, Brian
Lai, Zhongwu
Markovets, Aleksandra
Felip, Enriqueta
Vivancos, Ana
Kuang, Yanan
Sholl, Lynette
Redig, Amanda J.
Cantarini, Mireille
Barrett, J. Carl
Pillai, Rathi N.
Cho, Byoung Chul
Lacroix, Ludovic
Planchard, David
Soria, Jean Charles
Jaenne, Pasi A.
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S207 - S207
[24] Epidermal Growth Factor Receptor (EGFR) T790M Testing in EGFR-mutated Non-Small Cell Lung Cancer: A Successful Model of Personalized Cancer Care Beyond Resistance
Moskovitz, Mor
ISRAEL MEDICAL ASSOCIATION JOURNAL, 2019, 21 (06): : 416 - 418
[25] Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity
Marcar, Lynnette
Bardhan, Kankana
Gheorghiu, Liliana
Dinkelborg, Patrick
Pfaffle, Heike
Liu, Qi
Wang, Meng
Piotrowska, Zofia
Sequist, Lecia V.
Borgmann, Kerstin
Settleman, Jeffrey E.
Engelman, Jeffrey A.
Hata, Aaron N.
Willers, Henning
CELL REPORTS, 2019, 27 (12): : 3422 - +
[26] EGFR-mutated lung cancer: a paradigm of molecular oncology
Zhang, Zhenfeng
Stiegler, Amy L.
Boggon, Titus J.
Kobayashi, Susumu
Halmos, Balazs
ONCOTARGET, 2010, 1 (07) : 497 - 514
[27] Exosomes: a new perspective in EGFR-mutated lung cancer
Amina Jouida
Cormac McCarthy
Aurelie Fabre
Michael P. Keane
Cancer and Metastasis Reviews, 2021, 40 : 589 - 601
[28] A novel theranostic target for EGFR-mutated lung cancer
Tsukumo, Yoshinori
Ohoka, Nobumichi
Naito, Mikihiko
Suzuki, Takayoshi
CANCER SCIENCE, 2022, 113 : 1151 - 1151
[29] What management for epidermal growth factor receptor-mutated non-small-cell lung cancer, with squamous cell transformation and T790M-acquired resistance mechanisms? A Case report and review of literature
Helissey, Carole
Favre, Loetitia
Nguyen, Anh Tuan
Mamou, Elodie
Lamboley, Jean-Laurent
ANTI-CANCER DRUGS, 2022, 33 (01) : E720 - E723
[30] Exosomes: a new perspective in EGFR-mutated lung cancer
Jouida, Amina
McCarthy, Cormac
Fabre, Aurelie
Keane, Michael P.
CANCER AND METASTASIS REVIEWS, 2021, 40 (02) : 589 - 601

← 1 2 3 4 5 →